Creating, facilitating and promoting sustainable Health Technology Assessment (HTA) cooperation in Europe
EUnetHTA Magazine Summer 2021 – now available
We are pleased to publish the EUnetHTA Magazine for Summer 2021, the last issue of Joint Action 3 (2016-2021). While the magazine is intended to
PTJA16 – Venetoclax in combination with an hypomethylating agent for treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy – final assessment now available
This is the pharmaceutical Joint Assessment PTJA16 – Venetoclax with a hypomethylating agent fort he treatment of adult patients with newly diagnosed acute myeloid leukaemia
EUnetHTA and EMA take stock of their cooperation
The European Network for Health Technology Assessment (EUnetHTA) and the European Medicines Agency (EMA) have published a Technical Report on their achievements since 2017.
EUnetHTA-EMA April Meeting – minutes now available
We are pleased to publish the minutes for the EUnetHTA-EMA Bilateral meeting held online on 28 April, 2021. This meeting concluded the EMA/EUnetHTA work plan
PTRCR20 – Bamlanivimab for the treatment of COVID-19 Rapid Collaborative Review- Final Rapid Collaborative Review now available.
This is the fourth pharmaceutical Rapid Collaborative Review (PTRCR20) published by EUnetHTA. In March 2021, after an Article 5(3) review the European Medicines Agency (EMA) endorsed
PTJA17 – Elivaldogene autotemcel (eli-cel) for treatment of cerebral adrenoleukodystrophy (CALD) – project plan now available
The final project plan of the relative effectiveness assessment of ‘Elivaldogene autotemcel (eli-cel) for treatment of cerebral adrenoleukodystrophy (CALD)’ is now available for access. The
COVID-19 Response
EUnetHTA has prioritised COVID-19-related initiatives above other work during the current time. Here you will find updated information and publications relating to COVID-19 diagnostic testing, therapeutic treatments, and useful links to further data from our network partners.
Services
EUnetHTA develops several services that help inform the decision-making process around the introduction of pharmaceuticals and other technologies at the national, regional, and European levels. These include Joint Assessments, Early Dialogues, and Post Launch Evidence Generation (PLEG). Find out more here.
Assessments
Pharmaceutical Joint Assessments (PTJA) and Other Technologies Collaborative Assessments (OTCA) are key EUnetHTA outputs. Find current project status, EUnetHTA Prioritisation List (EPL) and Topic Identification, Selection, and Prioritisation (TISP), uptake data and archived content here.
Tools
EUnetHTA has developed a suite of tools to complement all steps in the collaborative joint work process, helping partners to proceed with a defined methodology. Access all current and archived tools here.
Get Involved
EUnetHTA functions as a collaboration between network members and exterior partners to develop joint work. These include patients, industry, regulators, HCPs, and payers. Find out more about partner involvement, activities, and EUnetHTA events here.
